MYBPC3 and left ventricular hypertrophy: The training cohort focused on obstructive HCM, the most prevalent symptomatic subtype (Saddique et al., 2025), with genetic specificity controlled by an independent MYBPC3 truncation mutation subgroup and secondary hypertrophy excluded by ruling out aortic stenosis-related left ventricular hypertrophy (LVH) (Ananthamohan et al., 2024).